HRTX Stock Forecast: Heron Therapeutics, Inc. Price Predictions for 2026-2027

Last close, 20 Nov 2026
$0.25
−2.88% on the day

The median 12-month analyst price target for Heron Therapeutics, Inc. is $7. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 54 of 100 as at 21 Nov 2026 — in the upper half.

Market cap
$49.5M
Ticker Nerd rank
54/ 100
Median analyst target
$7.00
Analysts covering
2
Revenue$37.7M+1.3% y/y
Operating income−$2.0M
Net income−$5.5M
Free cash flow−$2.4M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−18.5%
1M
−27.9%
YTD
−80.6%
1Y
−76.2%
From 52W high
−83.1%
From 52W low
0.0%
$0.25
$1.49
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

One number for the whole business

Consensus tells you what everyone already believes. The model scores Heron Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 21 Nov 2026
54/ 100

Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Quality
96
Value
89
Issuance
67
Accruals
49
Revisions
30
Volatility
29
Growth
19
Momentum
18

Quality (96): The business earns solid, repeatable profits on what it owns.

Momentum (18): The shares have been drifting down relative to others.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

HRTX stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on HRTX, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0.00$2.00$4.00$6.00$8.00$10.00Jan 26Apr 26Jul 26Oct 26HRTXHigh $9.00Median $7.00Low $5.00

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says2 analysts
0
Buy
2
Hold
0
Sell
$5.00
Low
$7.00
Median
$9.00
High
Recent analyst actionsNewest first
DateFirmActionRatingTarget
11 Aug 2026HC Wainwright & Co.DowngradeNeutral—
3 June 2026HC Wainwright & Co.MaintainsBuy$4.00 → $2.00
3 June 2026NeedhamDowngradeHold—
9 Jan 2026HC Wainwright & Co.ReiteratesBuy—
8 Aug 2025NeedhamMaintainsBuy—
9 June 2025HC Wainwright & Co.InitiatesBuy—
11 Apr 2025NeedhamReiteratesBuy—
28 Feb 2025NeedhamReiteratesBuy—
4 Dec 2024NeedhamReiteratesBuy—
13 Nov 2024NeedhamMaintainsBuy—
25 Sept 2024NeedhamReiteratesBuy—
7 Aug 2024NeedhamReiteratesBuy—
13 June 2024Rodman & RenshawInitiatesBuy—
16 May 2024NeedhamReiteratesBuy—
8 May 2024NeedhamReiteratesBuy—
23 Apr 2024Capital OneInitiatesOverweight—
11 Apr 2024NeedhamReiteratesBuy—
13 Mar 2024NeedhamMaintainsBuy—
15 Nov 2023NeedhamMaintainsBuy—
15 Aug 2023NeedhamReiteratesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for HRTX.

Market Radar

This page is one stock. Monday covers all of them.

HRTX appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.

Free. Unsubscribe any time. Privacy

The AI build-out map
PDF
  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and servers

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

HRTX vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 20 Nov 2026, Heron Therapeutics, Inc. returned −76.2% against +6.9% for the S&P 500, dividends included.

HRTX vs S&P 500, last 12 monthsTotal return, rebased to 100
20406080100120140Jan 26Apr 26Jul 26Oct 26HRTXS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

HRTX analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
Analysts raising
0
Analysts cutting
1
Fundamentals

Financials

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
—
Price / sales
0.3×

Cheaper than 85% of US stocks

Price / book
13.2×

Cheaper than 5% of US stocks

EV / EBITDA
—
Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
69.3%

Higher than 82% of US stocks

Operating margin
−5.7%

Higher than 29% of US stocks

Net margin
—
Returns & dividend
Return on equity
−217.8%

Higher than 7% of US stocks

Return on assets
−2.2%

Higher than 37% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.

Statistics

Key statistics

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Heron Therapeutics, Inc. has a market value of $49.5M and an enterprise value of $159.6M.

  • Revenue in the twelve months to 30 June 2026: $151.2M. The latest quarter grew 1.3% year on year.

  • Net income over the same four quarters: −$34.0M, a −22.5% net margin.

  • Diluted earnings per share, trailing twelve months: −$0.19.

  • Free cash flow in the twelve months to 30 June 2026: −$12.1M.

  • Shares outstanding: 189.5M.

  • Heron Therapeutics, Inc. employs 128 people — $1.2M of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 20 Nov 2026

Data provided by Twelve Data

Peers

HRTX and its peers

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
HRTXHeron Therapeutics, Inc.$49.5M54
CNXUConexeu Sciences, Inc.$47.8M1
ONCYOncolytics Biotech, Inc.$47.7M38
VRCAVerrica Pharmaceuticals, Inc.$47.1M49
IMAImageneBio, Inc.$48.8M33
ACRVAcrivon Therapeutics, Inc.$49.2M65
TNXPTonix Pharmaceuticals Holding Corp.$46.2M22

Take a look at HRTX’s peer groups, ranked by the model: healthcare stocks · biotech stocks.

Look up any of the roughly 4,300 stocks we score.

The rank is the raw material. Whether the rules would actually own Heron Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

FAQ

Questions about HRTX

What is the HRTX stock price forecast for 2026-2027?

The median 12-month analyst price target for Heron Therapeutics, Inc. is $7, with estimates ranging from $5 to $9. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is HRTX stock a buy right now?

Of the 2 analysts covering Heron Therapeutics, Inc., 0 rate it a Buy, 2 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Heron Therapeutics, Inc. 54 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank HRTX?

As at 21 Nov 2026, Heron Therapeutics, Inc. ranks 54 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Quality (96 of 100).

Will HRTX stock go up?

No one can know that. What the data says: the median 12-month target from 2 analysts is $7, and Ticker Nerd's factor model ranks Heron Therapeutics, Inc. 54 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the HRTX stock forecast for 2030?

No analyst covering Heron Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for HRTX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $5 to $9 over the next 12 months.

How has HRTX stock performed over the past year?

Heron Therapeutics, Inc. returned -76.2% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Heron Therapeutics, Inc. do?

Heron Therapeutics, Inc. is a commercial-stage biotechnology company focused on developing and marketing therapies for acute care and oncology supportive care. The company’s current portfolio includes products used to help manage post-surgical pain and to prevent nausea and vomiting associated with surgery and cancer treatment.

Company

About Heron Therapeutics, Inc.

Heron Therapeutics, Inc. is a commercial-stage biotechnology company focused on developing and marketing therapies for acute care and oncology supportive care. The company’s current portfolio includes products used to help manage post-surgical pain and to prevent nausea and vomiting associated with surgery and cancer treatment. Its marketed medicines are designed for use in clinical settings and are sold primarily through healthcare providers, hospitals, and other medical institutions. Heron Therapeutics relies on proprietary drug delivery and formulation capabilities to support its branded prescription products, which serve specialized patient needs in perioperative care and oncology. The company operates in the U.S. specialty pharmaceutical market and is positioned around targeted treatments that address common complications of medical procedures and cancer therapy.

CEO Mr. Craig Alexander Collard · 128 employees · United States · https://www.herontx.com